Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Terns Pharmaceuticals, Inc. (TERN : NSDQ)

• Company Description    Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY, Calif. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $3.83 Daily Weekly Monthly 20 Day Moving Average: 914,231 shares Shares Outstanding: 87.34 (millions) Market Capitalization: $334.50 (millions) Beta: -0.18 52 Week High: $11.40 52 Week Low: $1.87 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 23.15% 17.94% 12 Week 82.38% 49.91% Year To Date -30.87% -34.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1065 EAST HILLSDALE BLVD. SUITE 100 - FOSTER CITY,CA 94404 USA ph: 650-525-5535 fax: - investors@ternspharma.com http://www.ternspharma.com

• General Corporate Information    Officers Amy Burroughs - Chief Executive Officer and Director David Fellows - Chairman of the Board of Directors Andrew Gengos - Chief Financial Officer Robert Azelby - Director Jeffrey Kindler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 880881107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 87.34 Most Recent Split Date: (:1) Beta: -0.18 Market Capitalization: $334.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.03 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 13.33% vs. Previous Quarter: -8.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - -28.81 12/31/24 - -30.49 09/30/24 - -32.76 ROA 03/31/25 - -27.55 12/31/24 - -29.14 09/30/24 - -31.33 Current Ratio 03/31/25 - 30.89 12/31/24 - 23.14 09/30/24 - 32.99 Quick Ratio 03/31/25 - 30.89 12/31/24 - 23.14 09/30/24 - 32.99 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - 3.73 12/31/24 - 4.07 09/30/24 - 5.18 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©